3 days Ago By ABMN Staff
CIBC Private Wealth Group LLC reduced its position in shares of Inspire Medical Systems, Inc. ( NYSE:INSP – Free Report ) by 9.7% during the fourth quarter, Holdings Channel.
com reports. The fund owned 1,160 shares of the company’s stock after selling 125 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Inspire Medical Systems were worth $215,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of Inspire Medical Systems by 99.7% in the 3rd quarter.
BNP Paribas Financial Markets now owns 4,711 shares of the company’s stock worth $994,000 after purchasing an additional 2,352 shares during the last quarter. Captrust Financial Advisors acquired a new position in Inspire Medical Systems in the third quarter worth approximately $628,000. Verition Fund Management LLC acquired a new position in Inspire Medical Systems in the third quarter worth approximately $757,000.
Quarry LP increased its holdings in shares of Inspire Medical Systems by 30.9% in the third quarter. Quarry LP now owns 449 shares of the company’s stock valued at $95,000 after buying an additional 106 shares in the last quarter.
Finally, State Street Corp lifted its position in shares of Inspire Medical Systems by 78.0% during the 3rd quarter. State Street Corp now owns 1,049,784 shares of the company’s stock valued at $221,557,000 after acquiring an additional 459,990 shares during the last quarter.
94.91% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades INSP has been the topic of a number of recent research reports.
Royal Bank of Canada restated an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a report on Tuesday, February 11th. Morgan Stanley dropped their price target on Inspire Medical Systems from $230.
00 to $220.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. KeyCorp reaffirmed an “overweight” rating and set a $234.
00 price objective (down from $236.00) on shares of Inspire Medical Systems in a research note on Friday, January 24th. Truist Financial dropped their target price on shares of Inspire Medical Systems from $250.
00 to $235.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. Finally, Robert W.
Baird reduced their price target on shares of Inspire Medical Systems from $252.00 to $248.00 and set an “outperform” rating for the company in a research report on Tuesday, February 11th.
Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $226.
70. Inspire Medical Systems Stock Down 5.3 % Shares of NYSE:INSP opened at $141.
49 on Monday. The firm has a fifty day moving average of $175.94 and a two-hundred day moving average of $188.
07. Inspire Medical Systems, Inc. has a 12-month low of $123.
00 and a 12-month high of $257.40. The firm has a market capitalization of $4.
21 billion, a P/E ratio of 81.78, a price-to-earnings-growth ratio of 2.86 and a beta of 1.
39. Inspire Medical Systems ( NYSE:INSP – Get Free Report ) last issued its quarterly earnings data on Monday, February 10th. The company reported $1.
15 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.41.
Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%.
Equities research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.
Insider Transactions at Inspire Medical Systems In related news, insider Randy Ban sold 25,584 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.
00. Following the completion of the transaction, the insider now owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50.
The trade was a 77.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, CTO John Rondoni sold 583 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.
67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares of the company’s stock, valued at $1,777,187.76.
This represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
In the last quarter, insiders sold 26,225 shares of company stock worth $4,806,530. 4.10% of the stock is owned by corporate insiders.
About Inspire Medical Systems ( Free Report ) Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. Further Reading Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. ( NYSE:INSP – Free Report ). Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.
com's FREE daily email newsletter ..
